Pulmonary hypertension: Are we missing a key driver of vascular remodeling?

Pulmonary arterial hypertension (PAH) is a devastating condition characterized by increased pulmonary vascular resistance and right ventricular failure. The disease's progression is driven by a cascade of events, beginning with endothelial dysfunction and culminating in profound vascular remodeling. This remodeling involves the proliferation of pulmonary artery smooth muscle cells, activation of fibroblasts, and excessive deposition of extracellular matrix, all contributing to the narrowing of pulmonary arteries.¹

Endothelial dysfunction, an early and central event in PAH, disrupts the delicate balance between vasodilators and vasoconstrictors. It also increases vascular permeability and promotes a pro-thrombotic state within the pulmonary vasculature. These initial changes set the stage for the subsequent and more severe vascular alterations that define PAH. Identifying and targeting these early pathogenic mechanisms is paramount for developing truly disease-modifying therapies.¹

The IGF Family's Role in PAH Pathogenesis

Recent evidence highlights the significant contribution of the insulin-like growth factor (IGF) family to both vascular remodeling and endothelial dysfunction in PAH. The IGF family encompasses insulin-like growth factors (IGFs), IGF binding proteins (IGFBPs), and IGFBP-related proteins (IGFBPLs). These molecules operate through intricate signaling networks involving IGF receptors and various regulatory proteins, directly influencing cellular processes critical to PAH.¹

Specifically, IGFs promote the proliferation of pulmonary artery smooth muscle cells, a hallmark of vascular remodeling in PAH. They also drive the accumulation of extracellular matrix, further stiffening and narrowing the pulmonary arteries. These actions directly aggravate the vascular alterations characteristic of the disease, suggesting that the IGF pathway is not merely an incidental bystander but an active participant in disease progression.¹

The review by Li, Mo, and Dai, published in Frontiers in Physiology, consolidates current evidence on the IGF family's roles in PAH pathogenesis.¹ The authors emphasize its contributions to vascular remodeling, endothelial dysfunction, and right ventricular adaptation. This comprehensive review aims to delineate the distinct yet interconnected actions of IGF-related molecules, with the ultimate goal of identifying potential diagnostic biomarkers and therapeutic targets for PAH management.¹

Mechanistic Insights into IGF Signaling

The IGF system is complex, involving IGF-1 and IGF-2, their respective receptors (IGF-1R and IGF-2R), and a series of six high-affinity IGFBPs (IGFBP-1 to -6) that modulate IGF bioavailability and activity. IGF-1R, a tyrosine kinase receptor, mediates most of the anabolic and anti-apoptotic effects of IGFs. Activation of IGF-1R triggers downstream signaling pathways, including the PI3K/Akt and MAPK/ERK pathways, which are known to regulate cell proliferation, survival, and migration. In the context of PAH, aberrant activation of these pathways in pulmonary vascular cells contributes to the uncontrolled growth and survival of smooth muscle cells.¹

IGF-1, in particular, has been shown to be elevated in the serum and lung tissue of patients with PAH. This elevation correlates with disease severity and progression. IGF-1 promotes the proliferation of human pulmonary artery smooth muscle cells (HPASMCs) and inhibits their apoptosis, leading to an accumulation of these cells in the pulmonary arterial wall. This effect is mediated through the IGF-1R and its downstream signaling cascades, which are often dysregulated in PAH.¹

But the role of IGFBPs is equally critical. These proteins bind IGFs with high affinity, regulating their access to receptors and thus modulating their biological activity. Some IGFBPs inhibit IGF action by sequestering them, while others can enhance IGF effects or exert IGF-independent actions. For instance, IGFBP-3, the most abundant IGFBP, can either inhibit or potentiate IGF-1 actions depending on the cellular context and its proteolytic state. Dysregulation of specific IGFBPs in PAH could therefore contribute to the pathological effects of IGFs.¹

The review also touches upon IGFBP-related proteins (IGFBPLs), a less characterized subgroup within the IGF family. While their specific involvement in PAH is still being elucidated, these proteins are known to participate in various cellular processes, including cell adhesion, migration, and angiogenesis. Their potential contribution to the complex vascular remodeling seen in PAH warrants further investigation. Understanding the precise roles of individual IGFBPs and IGFBPLs could uncover more specific therapeutic targets.¹

Impact on Endothelial Dysfunction and Vascular Remodeling

Endothelial dysfunction is not merely an initiating event; it actively contributes to the perpetuation of vascular remodeling. Impaired endothelial cell function leads to reduced production of vasodilators like nitric oxide and prostacyclin, while increasing vasoconstrictors such as endothelin-1. This imbalance drives sustained vasoconstriction and promotes further smooth muscle cell proliferation. IGFs exacerbate this dysfunction by promoting endothelial cell apoptosis and impairing their regenerative capacity, creating a vicious cycle that accelerates disease progression.¹

The vascular remodeling in PAH is characterized by a significant increase in the medial thickness of pulmonary arteries, due to the proliferation and migration of smooth muscle cells. Fibroblast activation and excessive extracellular matrix deposition also contribute to this structural reorganization, leading to increased stiffness and reduced compliance of the pulmonary vasculature. IGFs directly stimulate these processes, acting as potent mitogens for smooth muscle cells and enhancing fibroblast activity. This makes the IGF pathway a central player in the structural changes that ultimately lead to right ventricular failure.¹

The right ventricle (RV) in PAH initially adapts to the increased afterload by undergoing hypertrophy. But sustained pressure overload eventually leads to RV dysfunction and failure, which is the primary cause of death in PAH patients. The IGF family also influences RV adaptation. While IGF-1 can initially support physiological hypertrophy, chronic activation and dysregulation of the IGF pathway can contribute to pathological remodeling and fibrosis in the RV, ultimately leading to decompensation. This dual role suggests that targeting IGFs must be carefully considered to avoid unintended consequences on cardiac function.¹

Potential for Diagnostic Biomarkers and Therapeutic Targets

The intricate involvement of the IGF family in PAH pathogenesis positions its components as promising candidates for diagnostic biomarkers, as measuring circulating levels of IGFs or specific IGFBPs could provide insights into disease activity, severity, and prognosis. For example, persistently elevated IGF-1 levels might indicate ongoing vascular remodeling and a higher risk of progression. Such biomarkers could aid in early diagnosis and help monitor treatment response, guiding precision strategies for PAH management.¹

From a therapeutic perspective, modulating the IGF pathway offers several avenues. Inhibiting IGF-1R signaling, for instance, could reduce pulmonary artery smooth muscle cell proliferation and extracellular matrix deposition. Small molecule inhibitors targeting IGF-1R have been developed for various cancers, and their potential application in PAH warrants investigation. But the widespread physiological roles of IGFs mean that systemic inhibition could lead to significant off-target effects, necessitating highly specific approaches.¹

Alternatively, targeting specific IGFBPs that promote pathological IGF actions could offer a more tailored approach. For example, if a particular IGFBP is found to enhance IGF-mediated smooth muscle cell proliferation, developing an antagonist for that specific binding protein could selectively mitigate the detrimental effects without broadly disrupting IGF signaling. This precision approach aligns with the growing understanding of PAH as a heterogeneous disease requiring tailored interventions. Clinicians seeking to deepen their understanding of complex cardiovascular conditions might find the Braunwald's Heart Disease textbook a valuable resource for such intricate pathways.¹

The review also highlights the need for further research to fully characterize the specific involvement of each IGF family member in PAH. While the IGF family has been implicated in a range of cardiovascular disorders, its precise role in PAH remains insufficiently detailed. Future studies should focus on delineating the distinct yet interconnected actions of IGF-related molecules, potentially through genetic studies, animal models, and human translational research. This will be essential for translating these mechanistic insights into effective clinical strategies, as the stakes are the development of effective clinical strategies.¹

But the complexity of the IGF system presents a challenge. The redundancy and compensatory mechanisms within the IGF pathway mean that simply blocking one component might not yield the desired therapeutic effect. Combination therapies, targeting multiple aspects of the IGF system or combining IGF modulation with existing PAH therapies, could be more effective. This approach has shown promise in other complex diseases and might be necessary to overcome the robust pathological mechanisms in PAH.¹

The open-label design of much of the mechanistic research on IGFs is an obvious caveat. While in vitro and animal studies provide strong evidence for the involvement of IGFs, clinical validation in well-designed human trials is still largely absent. The direct translation of these findings into human therapeutics requires rigorous testing to confirm efficacy and safety. This gap matters, as many preclinical targets fail in human trials due to unforeseen complexities in human physiology. For those interested in the broader context of pulmonary conditions, our previous coverage on novel adaptive study programmes for PAH offers additional perspectives on therapeutic development.¹

The review by Li, Mo, and Dai provides a comprehensive overview, but it is a review, not a primary research paper presenting new data. It synthesizes existing knowledge, which is valuable, but it does not offer novel experimental evidence or clinical trial results. The conclusions drawn are based on the aggregation of prior studies, some of which may have their own limitations in terms of methodology or generalizability. Therefore, while the IGF family is a compelling target, the field still requires definitive clinical trials to establish its therapeutic utility.¹